Lamivudine/Zidovudine Arrow (Zidovudine, Lamivudine)

Both lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors. After oral absorption they are converted inside cells to active triphosphate forms that compete with natural nucleotides, blocking HIV reverse transcriptase and preventing synthesis of viral DNA, which stops viral replication.

The dosing regimen for Lamivudine/Zidovudine is individualized and must be determined by a qualified prescriber based on the patient’s age, weight, renal function, and overall treatment plan. Patients should follow the exact instructions provided by their healthcare professional.

Data on the use of lamivudine/zidovudine during pregnancy are limited, and the drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding decisions should be made in consultation with a physician, considering the infant’s exposure risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/zidovudine is a well‑established NRTI backbone often combined with a protease inhibitor or an integrase inhibitor. Compared with newer combinations such as tenofovir/emtricitabine, it may have a different safety profile, including a higher incidence of anemia, but remains effective for patients with specific resistance patterns.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Tablets should be kept in a dry place and out of reach of children.

Lamivudine/Zidovudine is taken orally, usually as a tablet, with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals for optimal absorption.

Serious adverse events include severe anemia, lactic acidosis, hepatic steatosis, and bone‑marrow suppression. Patients should be monitored regularly for hematologic changes, liver function abnormalities, and signs of metabolic disturbances, and should seek immediate medical attention if severe symptoms develop.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any component of the formulation should avoid this medication. It is also contraindicated in patients with severe bone‑marrow suppression or uncontrolled hepatic disease, and caution is advised in those with significant renal impairment.